- Net sales increased by 10.5% to $191.9
million
- Net earnings increased by 16.4%, while
earnings per share increased by 26.7% to $1.47
- Number of active Associates increased
by 18.8%
- Company repurchased approximately 1.1
million shares during third quarter
USANA Health Sciences, Inc. (NYSE: USNA) today announced
financial results for its fiscal third quarter ended September 27,
2014. The Company also provided updated net sales and earnings
guidance for 2014.
Financial Performance
For the third quarter of 2014, net sales increased by 10.5% to
$191.9 million, compared with $173.7 million in the prior-year
period. The increase in net sales was driven by overall Associate
growth of 18.8%, which was generated by the Company’s Asia Pacific
region.
Net earnings for the third quarter increased by 16.4% to $19.5
million, compared with $16.8 million during the prior-year period.
This increase was driven by higher net sales and lower relative
Associate Incentives expense. On a relative basis, Associate
Incentives expense declined due to a $4.5 million one-time payout
resulting from the pricing and compensation plan initiatives
implemented by the Company in the third quarter of 2013. Earnings
per share for the quarter increased by 26.7% to $1.47, compared
with $1.16 in the third quarter of the prior year. This increase in
earnings per share was attributable to higher net earnings and a
lower number of diluted shares outstanding due to the Company’s
share repurchases during 2014. Weighted average diluted shares
outstanding were 13.3 million as of the end of the third quarter of
2014, compared with 14.4 million in the prior-year period.
Top and bottom line results for the third quarter benefitted
from the recognition of $3.1 million of deferred revenue in Hong
Kong. Earnings per share for the quarter benefitted by $0.11 as a
result of this revenue recognition.
During the quarter, the Company repurchased approximately 1.1
million shares under its authorized repurchase program for a total
investment of $76.6 million. Additionally, as of October 24, 2014,
the Company has subsequently invested $13.2 million to repurchase
approximately 172,000 shares pursuant to a Rule 10b5-1 plan. As of
October 24, 2014, there were $61.2 million remaining under the
current share repurchase authorization. The Company ended the third
quarter with approximately $87.7 million in cash and cash
equivalents and $10 million on its revolving line of credit.
“USANA generated solid operating results in the third quarter,
which included double-digit sales, earnings and customer growth,”
said Kevin Guest, USANA’s President. “We also continued to see
impressive growth in world-wide unit volume, Auto Order sales and
check earners. This growth was driven by the pricing and
compensation plan enhancements we made a year ago and our
management team’s continued promotion of those enhancements during
2014. While we are pleased with the growth in each of these
metrics, customer growth continues to be our highest priority, as
we seek to improve the overall health and nutrition of individuals
and families around the world.”
Regional Results
Net sales in the Asia Pacific region increased by 21.3% to
$130.2 million, compared with $107.4 million for the third quarter
of the prior year, and increased 4.5% sequentially. The
year-over-year increase was due to 29.2% sales growth in the
Greater China region and 10.6% sales growth in the Southeast Asia
Pacific region. Sales growth in Greater China was driven by
double-digit sales and customer growth in Mainland China, while
sales growth in Southeast Asia Pacific resulted from strong sales
and customer growth in Australia/New Zealand, the Philippines and
Thailand. The number of active Associates in the Asia Pacific
region increased by 28.2% year-over-year, due primarily to
double-digit Associate growth in the Greater China and Southeast
Asia Pacific regions.
Net sales in the Americas/Europe region declined 6.9% to $61.7
million, due primarily to a sales decline in the U.S., which was
partially offset by net sales growth in other markets in the
region. The number of active Associates in this region declined
slightly compared to the prior-year period.
Outlook
The Company provided the following updated consolidated net
sales and earnings per share outlook for 2014:
- Consolidated net sales between $780
million and $790 million, versus the previous outlook of between
$770 and $790 million
- Earnings per share between $5.85 and
$5.95, versus the previous outlook of between $5.50 and $5.65
Chief Financial Officer, Paul Jones, commented, “As we head into
the final quarter of 2014, we are tightening our guidance range for
the topline and raising the outlook for EPS. The increase in our
EPS outlook is the result of another quarter of share repurchases
and lower than expected promotional costs. We are confident in the
strategies that we have in place and expect USANA to deliver
another year of record results.”
Conference Call
Shortly following the issuance of this earnings release, the
Company will post a new document titled “Management Commentary,
Results and Outlook” on the Company’s website
(www.usanahealthsciences.com) under the “Investor Relations”
section of the site. USANA will hold a conference call and webcast
to discuss this announcement with investors on Wednesday, October
29, 2014 at 11:00 AM Eastern Time. Investors may listen to the
call by accessing USANA’s website at
http://www.usanahealthsciences.com. The call will consist of
brief remarks by the Company’s management team, before moving
directly into questions and answers.
About USANA
USANA develops and manufactures high-quality nutritional,
personal care, and weight-management products that are sold
directly to Associates and Preferred Customers throughout the
United States, Canada, Australia, New Zealand, Hong Kong, China,
Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the
Philippines, the Netherlands, the United Kingdom, Thailand, France,
Belgium and Colombia. More information on USANA can be found at
http://www.usanahealthsciences.com.
Safe Harbor
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of
the Securities Exchange Act. Our actual results could differ
materially from those projected in these forward-looking
statements, which involve a number of risks and uncertainties,
including global economic conditions generally, reliance upon our
network of independent Associates, the governmental regulation of
our products, manufacturing and marketing risks, adverse publicity
risks, and risks associated with our international expansion. The
contents of this release should be considered in conjunction with
the risk factors, warnings, and cautionary statements that are
contained in our most recent filings with the Securities and
Exchange Commission.
USANA Health Sciences, Inc. Consolidated
Statements of Earnings (In thousands, except per share data)
(Unaudited)
Quarter Ended Nine Months Ended
28-Sep-13 27-Sep-14 28-Sep-13 27-Sep-14
Net sales $ 173,691 $ 191,944 $ 531,909 $ 562,601 Cost of
sales 31,491 34,585 93,657
103,278
Gross profit 142,200 157,359 438,252 459,323
Operating expenses Associate incentives 76,361 82,605
224,017 242,577 Selling, general and administrative 41,145
45,499 126,527 133,282
Earnings from operations 24,694 29,255 87,708 83,464
Other income (expense) 76 (297 ) (33 )
125
Earnings before income taxes 24,770 28,958 87,675 83,589
Income taxes 8,017 9,460 28,933
28,253
NET EARNINGS $ 16,753 $ 19,498
$ 58,742 $ 55,336 Earnings per share -
diluted $ 1.16 $ 1.47 $ 4.16 $ 3.96 Weighted average shares
outstanding - diluted 14,393 13,263 14,132 13,964
USANA Health Sciences,
Inc. Consolidated Balance Sheets (In thousands)
(Unaudited)
As of As of
ASSETS 28-Dec-13 27-Sep-14 Current Assets Cash
and cash equivalents $ 137,343 $ 87,738 Securities
held-to-maturity, net 8,642 - Inventories 47,242 42,584 Prepaid
Expenses and Other current assets 35,818 32,190
Total current assets 229,045 162,512 Property and
equipment, net 59,180 66,310 Goodwill 18,243 18,092 Intangible
assets, net 42,329 41,482 Deferred income taxes 5,519 5,597 Other
assets 14,154 22,937
Total assets $ 368,470 $
316,930
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities Accounts payable $ 9,502 $ 6,551 Other current
liabilities 86,369 88,912 Line of Credit- short term -
10,000
Total current liabilities 95,871 105,463
Other long-term liabilities 1,211 1,256 Deferred
income taxes 10,866 10,763 Stockholders' equity 260,522
199,448
Total liabilities and stockholders' equity $
368,470 $ 316,930
USANA Health Sciences,
Inc. Sales by Region (Unaudited) (In thousands)
Quarter Ended 28-Sep-13 27-Sep-14
Region
Americas and Europe $ 66,294 38.2 % $ 61,723 32.2 %
Asia Pacific Southeast Asia Pacific 40,230 23.2 % 44,488
23.2 % Greater China 59,768 34.4 % 77,206 40.2 %
North Asia 7,399 4.2 % 8,527 4.4 % Asia
Pacific Total 107,397 61.8 % 130,221 67.8 %
Total $ 173,691 100.0 % $ 191,944 100.0 %
Active
Associates by Region (1) (Unaudited)
As of
28-Sep-13 27-Sep-14
Region
Americas and Europe 82,000 33.5 % 82,000 28.2 % Asia
Pacific Southeast Asia Pacific 60,000 24.4 % 70,000 24.1 %
Greater China 94,000 38.4 % 129,000 44.3 % North Asia
9,000 3.7 % 10,000 3.4 % Asia Pacific Total
163,000 66.5 % 209,000 71.8 % Total
245,000 100.0 % 291,000 100.0 %
(1) Associates are independent
distributors of our products who also purchase our products
fortheir personal use. We only count as active those Associates who
have purchased from us anytime during the most recent three-month
period, either for personal use or for resale.
Active Preferred Customers by Region
(2) (Unaudited)
As of 28-Sep-13
27-Sep-14
Region
Americas and Europe 58,000 81.7 % 57,000 74.0 % Asia
Pacific Southeast Asia Pacific 8,000 11.3 % 11,000 14.3 %
Greater China 3,000 4.2 % 3,000 3.9 % North Asia
2,000 2.8 % 6,000 7.8 % Asia Pacific Total
13,000 18.3 % 20,000 26.0 % Total
71,000 100.0 % 77,000 100.0 %
(2) Preferred Customers purchase our
products strictly for their personal use and are not permittedto
resell or to distribute the products. We only count as active those
Preferred Customers who havepurchased from us any time during the
most recent three-month period.
USANA Health Sciences, Inc.Investors contact:Patrique Richards,
801-954-7961Investor Relationsinvestor.relations@us.usana.comMedia
contact:Dan Macuga, 801-954-7280Public Relations
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024